290 related articles for article (PubMed ID: 28386777)
1. Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response.
Tamura R; Tanaka T; Miyake K; Yoshida K; Sasaki H
Brain Tumor Pathol; 2017 Apr; 34(2):62-77. PubMed ID: 28386777
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab changes vascular structure and modulates the expression of angiogenic factors in recurrent malignant gliomas.
Okamoto S; Nitta M; Maruyama T; Sawada T; Komori T; Okada Y; Muragaki Y
Brain Tumor Pathol; 2016 Apr; 33(2):129-36. PubMed ID: 26826105
[TBL] [Abstract][Full Text] [Related]
3. Current evidence of temozolomide and bevacizumab in treatment of gliomas.
Nanegrungsunk D; Onchan W; Chattipakorn N; Chattipakorn SC
Neurol Res; 2015 Feb; 37(2):167-83. PubMed ID: 25033940
[TBL] [Abstract][Full Text] [Related]
4. CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.
Nishikawa M; Inoue A; Ohnishi T; Yano H; Kanemura Y; Kohno S; Ohue S; Ozaki S; Matsumoto S; Suehiro S; Nakamura Y; Shigekawa S; Watanabe H; Kitazawa R; Tanaka J; Kunieda T
Cancer Med; 2021 Mar; 10(6):2013-2025. PubMed ID: 33543833
[TBL] [Abstract][Full Text] [Related]
5. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy.
Ishikawa E; Miyazaki T; Takano S; Akutsu H
Brain Tumor Pathol; 2021 Jul; 38(3):149-155. PubMed ID: 33977360
[TBL] [Abstract][Full Text] [Related]
7. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.
Wick W; Wick A; Weiler M; Weller M
Curr Neurol Neurosci Rep; 2011 Jun; 11(3):305-12. PubMed ID: 21279815
[TBL] [Abstract][Full Text] [Related]
8. Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.
Zhao S; Zhang Y; Wang L; Yang L; Zou L; Gao F
Cancer Biol Ther; 2019; 20(1):65-72. PubMed ID: 30136881
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab and Glioblastoma: Past, Present, and Future Directions.
Kim MM; Umemura Y; Leung D
Cancer J; 2018; 24(4):180-186. PubMed ID: 30119081
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic Therapy of High-Grade Gliomas.
Jo J; Wen PY
Prog Neurol Surg; 2018; 31():180-199. PubMed ID: 29393186
[TBL] [Abstract][Full Text] [Related]
11. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
Winkler F; Osswald M; Wick W
Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
[TBL] [Abstract][Full Text] [Related]
12. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
[TBL] [Abstract][Full Text] [Related]
14. Effect of Notch expression in glioma stem cells on therapeutic response to chemo-radiotherapy in recurrent glioblastoma.
Saito N; Aoki K; Hirai N; Fujita S; Iwama J; Hiramoto Y; Ishii M; Sato K; Nakayama H; Harashina J; Hayashi M; Izukura H; Kimura H; Ito K; Sakurai T; Yokouchi Y; Oharazeki T; Takahashi K; Iwabuchi S
Brain Tumor Pathol; 2015 Jul; 32(3):176-83. PubMed ID: 25665548
[TBL] [Abstract][Full Text] [Related]
15. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.
Zhang W; Fulci G; Buhrman JS; Stemmer-Rachamimov AO; Chen JW; Wojtkiewicz GR; Weissleder R; Rabkin SD; Martuza RL
Mol Ther; 2012 Jan; 20(1):37-45. PubMed ID: 21915104
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
18. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
19. [Anti-angiogenic therapy for malignant glioma].
Nagane M
Gan To Kagaku Ryoho; 2014 Feb; 41(2):141-7. PubMed ID: 24743191
[TBL] [Abstract][Full Text] [Related]
20. New Directions in Anti-Angiogenic Therapy for Glioblastoma.
Wang N; Jain RK; Batchelor TT
Neurotherapeutics; 2017 Apr; 14(2):321-332. PubMed ID: 28083806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
